SA
IKT icon

Sanctuary Advisors’s Inhibikase Therapeutics IKT Stock Holding History

Sanctuary Advisors’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.3K Buy
+22,801
New +$40.8K ﹤0.01% 2775
2026
Q1 		– Sell
-12,539
Closed -$25.7K – 2576
2025
Q4 		$25.7K Buy
+12,539
New +$20K ﹤0.01% 2398

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanctuary Advisors's IKT Position: Q2 2026 in Review

Sanctuary Advisors opened a new position in Inhibikase Therapeutics (IKT) in Q2 2026: 22,801 shares worth $46.3K. The stake represents ﹤0.01% of the portfolio and ranks #2775 among its holdings. This is a return to the name: Sanctuary Advisors previously reported a position in IKT as recently as Q4 2025.

Sanctuary Advisors first reported a position in IKT in Q4 2025 and has held it in 2 quarters since. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Sanctuary Advisors held 22,801 shares of Inhibikase Therapeutics worth $46.3K as of Q2 2026.
  • Inhibikase Therapeutics was a new Sanctuary Advisors position in Q2 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of Sanctuary Advisors's portfolio in Q2 2026, its #2775 holding.
  • Sanctuary Advisors first reported a position in Inhibikase Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.